NLRP3 and Cognitive impairment: In this study, we show that administration of either the NLRP3-inhibitor MCC950 or the caspase-1 inhibitor Ac-YVAD-CMK reduces mortality, reverses cognitive impairments, and rescues neuronal damages in mice that have undergone CLP.